Article
RIG-I is an intracellular checkpoint that limits CD8+ T-cell antitumor immunity
2023-05-17
Abstract excerpt
<h4>Background: </h4> Although a variety of immune checkpoint monoclonal antibodies have been approved for the treatment of cancers, the low response rate of immune checkpoint inhibitors limits their wide clinical application. Therefore, to explore new and broader immunotherapy targets to improve the response rate of CD8 + T cells will provide theoretical basis for clinical treatment of refractory malignant solid...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 982e32d9-4976-551b-a2b3-d34d58c6d590
- DOI
- 10.21203/rs.3.rs-2931210/v1
